The Venous Antithrombotic Effect of LF 1351 in the Rat following Oral Administration

 

PDF Download Buy Article Permissions and Reprints

Summary

The venous antithrombotic effects of a novel chemical entity, LF 1351, were investigated in rats following single oral administration, in comparison with i.v. administered heparin. LF 1351 demonstrated a dose-related antithrombotic effect in three models of venous thrombosis. The compound was approximately equipotent in two models involving complete stasis of the vena cava and administration of factor Xa or porcine serum, giving respective ED₅₀ values of 48.7 mg/kg and 36.7 mg/kg. LF 1351 was less effective in a model involving partial stasis in the presence of an endothelial lesion. In this case, the antithrombotic effect did not exceed 60-65%, the ED₅₀ being 150 mg/kg. Heparin (50-300 μg/kg; 7.5-45.0 U/kg) was effective in all three models. At the approximate ED₈₀ value against factor Xa-induced thrombosis (75 mg/kg) the antithrombotic effect of LF 1351 persisted for 6 h. The antithrombotic effect of LF 1351 (300 mg/kg) occurred without significant changes in APTT or thrombin time.

• References

• 1 Ofosu FA, Gray E. Mechanisms of action of heparin: applications to the development of derivatives of heparins and heparinoids with antithrombotic properties. Semin Thromb Hemostas 1988; 14: 9-17
  Article in Thieme ConnectPubMedGoogle Scholar
• 2 Marciniak E, Gora-Maslak G. Enhancement by heparin of thrombin-induced antithrombin III proteolysis: its relation to the molecular weight and anticoagulant activity of heparin. Thromb Res 1982; 28: 411-421
  CrossrefPubMedGoogle Scholar
• 3 Tollefsen M, Blank MK. Detection of a new heparin dependent inhibitor of thrombin in human plasma. J Clin Invest 1981; 68: 589-596
  CrossrefPubMedGoogle Scholar
• 4 Ofosu FA. Low-molecular weight heparins. Drug News and Perspectives 1989; 2: 141-145
  PubMedGoogle Scholar
• 5 Fareed J, Walenga JM, Hoppensteadt D, Racanelli A, Coyne E. Chemical and biological heterogenecity in low molecular weight heparins: implications for clinical use and standardization. Semin Thromb Hemostas 1989; 15: 440-463
  Article in Thieme ConnectPubMedGoogle Scholar
• 6 Nenci GG, Agnelli G. Clinical experience with low molecular weight heparins. Thromb Res 1990; Suppl XI 69-87
  PubMedGoogle Scholar
• 7 Merton RE, Thomas DP. Experimental studies on the relative efficacy of dermatan sulfate and heparin as antithrombotic agents. Thromb Haemostas 1987; 58: 839-842
  PubMedGoogle Scholar
• 8 Hoppensteadt D, Walenga JM, Fareed J. Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate and heparin. Thromb Res 1990; 60: 191-200
  CrossrefPubMedGoogle Scholar
• 9 Dawes J, Hodson BA, Pepper DS. The absorption, clearance and metabolic fate of dermatan sulfate administered to man - studies using a radioiodinated derivative. Thromb Haemostas 1989; 62: 945-949
  PubMedGoogle Scholar
• 10 Wessler S, Reimer M, Sheps M. Biologic assay of thrombosis inducing activity in human serum. J Appl Physiol 1957; 14: 943-946
  PubMedGoogle Scholar
• 11 Fareed J, Walenga JM, Kumar A, Rock A. A modified stasis thrombosis model to study the antithrombotic actions of heparin and its fractions. Semin Thromb Hemostas 1985; 11: 155-175
  Article in Thieme ConnectPubMedGoogle Scholar
• 12 Millet J, Theveniaux J, Pascal M. A new experimental model of venous thrombosis in rat involving partial stasis and slight endothelial alteration. Thromb Res 1987; 45: 123-133
  CrossrefPubMedGoogle Scholar
• 13 Van Ryn-McKenna J, Gray E, Weber E, Ofosu FA, Buchanan MR. Effects of sulfated polysaccharides on inhibition of thrombus formation initiated by different stimuli. Thromb Haemostas 1989; 61: 7-9
  PubMedGoogle Scholar
• 14 Walenga JM, Petitou M, Lormeau JC, Samama M, Fareed J, Choay J. Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis model using different thrombogenic challenges. Thromb Res 1987; 46: 187-198
  CrossrefPubMedGoogle Scholar
• 15 Marki WE, Wallis RB. The anticoagulant and antithrombotic properties of hirudins. Thromb Haemostas 1990; 64: 344-348
  PubMedGoogle Scholar
• 16 Robinson JA, Robinson HC. Control of chrondroitin sulfate biosynthesis. Biochem J 1981; 194: 839-846
  CrossrefPubMedGoogle Scholar
• 17 Sobue M, Habuchi H, Ito K, Yonekura H, Oguri K, Sakurai K, Kamohara S, Ueno Y, Noyori R, Suzuki S. P-D-Xylosides and their analogues as artificial initiators of glycosaminoglycan chain synthesis. Aglycone-related variation in their effectiveness in vitro and in ovo. Biochem J 1987; 241: 591-601
  CrossrefPubMedGoogle Scholar
• 18 Johnston LS, Keller JM. The effect of betaxylosides on heparan sulfate synthesis by SV40-transformed Swiss mouse 3T3 cells. J Biol Chem 1979; 254: 2575-2578
  PubMedGoogle Scholar
• 19 Sudhakaran PR, Sinn W, von Figura K. Initiation of altered heparan sulfate on beta-D-xyloside in rat hepatocytes. Hoppe Seyler’s Z Physiol Chem 1981; 362: 39-46
  CrossrefPubMedGoogle Scholar
• 20 Robinson HC, Lindahl U. Effect of cyclohexamide, beta-D-xylosides and beta-D-galactosides on heparin biosynthesis in mouse mastocytoma. Biochem J 1981; 194: 575-586
  CrossrefPubMedGoogle Scholar
• 21 Stevens RL, Austen KF. Effect of p-nitrophenyl-p-D-xyloside on proteoglycan and glycosaminoglycan biosynthesis in rat serosal mast cell cultures. J Biol Chem 1982; 257: 253-259
  PubMedGoogle Scholar